Early Interception

Routine mammography, though relatively available, (a) give most women a feeling of significant discomfort during the process (b) has mediocre performance and frequent false positive results that (c) lead to unnecessary biopsies and other diagnostic workup procedures contributing to anxiety and resulting in screening hesitance in the target population. The overarching goal of this research is to complement and in certain cases substitute with a (d) simple blood draw that can (e) achieve higher sensitivity and specificity while being less invasive and more available.

“INTERCEPT” is our next study in early breast cancer detection and assessment. Please join our waitlist if you are interested in participating in this research program. Our goal is to initiate this study in 2023.

INTERCEPT is being designed as an observational study for women over 40 years of age and all men and women at increased risk of breast cancer. We are currently working on the clinical study protocol and will update you with information about initiation of the study as soon as possible.


Read how our next generation liquid biopsy is bringing us closer to personalized medicine in BCRF blog: New Liquid Biopsy Technique May Help Personalize Breast Cancer Diagnosis and Prognosis.

Blog post in nature portfolio: Hiding in Plain Sight: Early, nano-sized signs of breast cancer detected by liquid biopsy

Breast cancer affects 1 in every 8 women in the United States and is currently the most prevalent cancer worldwide. Precise staging at diagnosis and prognosis are essential for patients. We now have an additional analyte, Oncosomes, that can aid us in the diagnostics workup.

Check out our publication in npj Breast Cancer, Multianalyte liquid biopsy to aid the diagnostic workup of breast cancer.